• Clinical significance of cancer-related isolated distal deep vein thrombosis (iDDVT) is unknown.
Introduction
Patients with cancer-related venous thromboembolism (VTE) have a poor prognosis that is characterized by a high risk of death, bleeding and VTE recurrence [1] [2] [3] . In the absence of a high risk of bleeding, the most recent international guidelines recommend extended anticoagulation in patients with active cancer who develop VTE [4] . Suggested factors that support stopping anticoagulant therapy in such patients include the presence of an isolated distal deep vein thrombosis (iDDVT) as the index VTE event [5, 6] . This suggestion is based on the fact that iDDVT is viewed as a less severe form of VTE than proximal DVT or PE, and its clinical importance is even sometimes questioned: indeed, in the case of iDDVT, in the absence of anticoagulant treatment, the risk of clot propagation is moderate (3-month rates of proximal extension < 10% and of PE < 1%), the risk of death (of any cause) is lower than for proximal DVT and PE patients [7, 8] and, in the long term, after stopping anticoagulants, iDDVT is associated with an at least 2-fold lower risk of VTE recurrence than in patients with proximal DVT or PE, and most recurrences are iDDVT [9] [10] [11] . However, those reassuring data come from studies where the number of patients with cancer-related iDDVT was low or absent. To date, no study has specifically assessed the prognosis and the management of cancer-related iDDVT [6] . Given that VTE is frequent in cancer patients and that iDDVT represents half of all lower limb DVTs detected on whole leg compression ultrasound (CUS) (the use of this diagnostic technique is rapidly increasing), there is an urgent need for data on prognosis after cancer-related iDDVT so as to better characterize its clinical significance and to guide its management [12] .
We, therefore, analyzed data from the multicenter prospective observational OPTIMEV (Optimisation de l'interrogatoire dans l' evaluation du risque thromboembolique veineux) cohort to assess the risk of death, VTE recurrence and bleeding among patients with cancer-related iDDVT [9] . Our secondary objective was to describe the therapeutic management of iDDVT in patients with cancer.
Methods
The OPTIMEV study is a large, French, multicenter, prospective, observational cohort of in-and outpatients referred to vascular medicine physicians for clinically suspected VTE and followed for 3 years thereafter. Its primary objective was to assess risk factors for the various presentations of VTE disease. The study protocol has been described elsewhere and is available on ClinicalTrials.gov (registration number: NCT00670540). In this substudy, we focused on OPTIMEV study patients with lower limb iDDVT and active cancer. Those patients were compared with patients with iDDVT but without cancer (matched 1:2 on age and sex) and with patients with isolated proximal DVT (i.e. with or without extension to deep calf veins but without PE) and cancer (matched 1:1 on age and sex).
Patients
In brief, consecutive patients aged at least 18 years, referred for clinically suspected VTE to the vascular medicine physicians of the 41 hospitals and 292 private practices participating in the study were enrolled. All eligible patients with a suspicion of symptomatic DVT of the lower limbs underwent a standardized bilateral whole leg CUS, which examined the entire deep venous network. Diagnosis of DVT was confirmed if there was incompressibility of the vein. Only clots ≥ 5 mm in diameter under compression on CUS were considered as distal DVT [13] . Among patients with suspected PE, the diagnosis of PE was confirmed according to the PIOPED criteria.
For the present sub-study, we included the following patients: (i) those whose index VTE event was an objectively confirmed symptomatic iDDVT and who had active cancer, defined as a newly diagnosed cancer (within 3 months after index VTE event) or receiving anti-neoplastic treatment of any type, or in palliative care; (ii) a random selection of patients with an objectively confirmed iDDVT and without cancer (either at time of diagnosis or during follow-up) matched (1:2) to patients with cancer-related iDDVT on age (three classes, ≤ 50, 51-75 and > 75 years) and sex; and (iii) a random selection of patients with an objectively confirmed cancer-related isolated proximal DVT matched (1:1) to patients with cancer-related iDDVT on age (3 classes, ≤ 50, 51-75 and > 75 years) and sex. Patients were excluded if they were not eligible for follow-up in OPTIMEV, namely patients who were enrolled in overseas territories, living outside of France or homeless.
Study protocol
At inclusion, demographic characteristics, clinical data and diagnostic test results were prospectively collected by the vascular medicine physician. At 3 months and thereafter every year for 3 years, patients were phoned by a clinical research assistant to obtain information on health-related events and their treatment since inclusion. The general practitioner or the vascular medicine physician was contacted whenever a possible event was disclosed or when the patient's history seemed potentially unreliable. Medical records were reviewed in the case of potential adverse events (death, VTE recurrence, bleeding, cancer or cardiovascular event), hospitalization or a new visit to the vascular medicine physician during the follow-up period.
The OPTIMEV study was approved by the Ethics Committee (Comit e Consultatif sur le Traitement de l'Information en mati ere de Recherche dans le domaine de la Sant e) and the CNIL (Commission Nationale de l'Informatique et des Libert es). In accordance with French legislation on medical research, we obtained oral informed consent from all patients.
Data collection
At enrolment, we collected the following data: demographics (age, gender and in-or outpatient status), risk factors for VTE (including recent surgery, immobilization, obesity, varicose veins, and personal and family [first and second-degree relatives] history of VTE) characteristics of the index DVT (unilateral or bilateral; proximal vs. distal and deep calf vs. muscular vein location), presence of active cancer and its characteristics (type, stage and treatments), and treatments.
Study outcomes
The study outcomes were recurrent VTE (DVT or PE), major bleeding (whether or not the patient was taking an anticoagulant) and overall mortality at 3 years. Recurrent VTE events were confirmed objectively according to ISTH criteria [14] . For the categorization of bleeding episodes, the ISTH definition was used [15] . An expert committee adjudicated all the clinical outcomes.
Statistical analysis
Follow-up for this analysis begins at patients' enrolment and was censored once a participant had died, stopped follow-up or had been followed for 3 years.
Categorical variables were expressed as frequencies and percentages and continuous variables were expressed as means and standard deviation (SD) or median and interquartile range (IQR).
Results in each group (cancer-related iDDVT, cancerrelated isolated proximal DVT and iDDVT without cancer) are given as incidence rates of each type of event (death, VTE recurrence and major bleeding), presented as events per 100 patient-years (PY). Cumulative rates of death and VTE recurrence were estimated with the Kaplan-Meier method.
Given that our cancer population was at high risk of death, we used Cox cause-specific hazard ratio models censoring at patients' deaths for our cause-specific analyses of rates of VTE recurrences (overall and after anticoagulant withdrawal) and major bleeding (i.e. etiologic questions regarding cancer-associated VTE), whereas we used Cox proportional hazards models to assess the risk of death [16] . Comparisons between groups (cancerrelated iDDVT vs. iDDVT without cancer and cancerrelated iDDVT vs. cancer-related isolated proximal DVT) were presented as crude hazard ratios (HRs) and crude cause-specific HRs (CHRs) and 95% confidence intervals (CIs), and HRs and CHRs with 95% CI adjusted for treatment (considered as a time-varying covariate) (anticoagulant treatment truly received by the patient; no adjustment of treatment in the case of assessment of recurrence after anticoagulant withdrawal), age, sex and obesity (BMI > 30 kg/m 2 ) (aHR and aCHR). In a sensitivity analysis, we repeated the analyses in the subgroups of patients without any history of previous VTE. We also calculated rates of death and VTE recurrence in patients with bilateral DVT (cancer-related iDDVT, cancer-related isolated proximal DVT and iDDVT without cancer).
Two-sided P values of 0.050 or less were considered to be statistically significant. Data were analyzed using Stata software (version 13.0, Stata Corp., College Station, Texas, USA).
Results
From November 2004 to January 2006, 8256 consecutive patients were enrolled in the OPTIMEV study ( Fig. 1 ). Of these, 92 had a symptomatic iDDVT and active cancer and were matched with 92 patients with a symptomatic cancer-related isolated proximal DVT and 184 patients with an iDDVT without cancer. Their main characteristics are depicted in Table 1 .
Characteristics of cancer
At baseline, 14.1% (n = 13) of cancer-related iDDVT patients and 16.3% (n = 15) of cancer-related isolated proximal DVT patients were undergoing palliative care. The proportions of patients who were receiving chemotherapy or who had radiotherapy or recent cancer surgery (< 45 days) were, for cancer-related iDDVT patients, respectively, 47.6% (n = 40), 9.5% (n = 8) and 14.3% (n = 12) and for cancer-related isolated proximal DVT patients, 60.5% (n = 49), 6.2% (n = 5) and 11.1% (n = 9). The different types and stages of cancer among patients with cancer-related iDDVT and cancer-related isolated proximal DVT are presented in Table 1 .
Management of index DVT event
At baseline, 17.4% (n = 16) of cancer-related iDDVT patients, 19 .6% (n = 18) of cancer-related isolated proximal DVT patients and 20.1% (n = 37) of iDDVT patients without cancer were receiving anticoagulant treatments at prophylactic doses.
Anticoagulants were prescribed to 90.2% (n = 83) of cancer-related iDDVT patients, at full doses in 95.5% of cases (n = 63) and for a median duration of 166 days (90-299) (duration calculated in patients who survived the 3 years of follow-up). In patients with cancer-related proximal DVT, 96.7% (n = 89) were prescribed anticoagulants, at full doses in 95.3% of cases (n = 61/64) and for a median duration of 273 days (151-740). In patients with iDDVT without cancer, all patients were prescribed anticoagulants, at full doses in 97.2% of cases (n = 172) and for a median duration of 92 days (62-212). Overall, 21.2% (n = 14) of patients with iDDVT and cancer, 24.6% (n = 16) of patients with proximal DVT and cancer and 13.4% (n = 24) of patients with iDDVT without cancer were treated with low-molecular-weight heparin (LMWH) without any vitamin K antagonist (VKA) switch.
Outcomes during follow-up
During the 3 years of follow-up, death occurred in 60.9% (n = 56) of cancer-related iDDVT patients, 58.7% (n = 54) of cancer-related isolated proximal DVT patients and 9.8% (n = 18) of iDDVT patients without cancer.
A comparison of incidences of death, VTE recurrence, recurrence after stopping anticoagulant treatment and major bleeding is provided in Table 2 . As compared with Among the 16 recurrences that occurred in patients with cancer-related iDDVT, 75% were proximal VTE events (six PE and six proximal DVT). Among the seven recurrences in patients with cancer-related isolated proximal DVT, all were proximal VTE events (three PE and four proximal DVT). Among the 23 recurrences in patients with iDDVT without cancer for whom the exact location of DVT (distal or proximal) was available, 52.2% (n = 12) were iDDVT and 47.9% (n = 11) were proximal VTE events (eight PE and three proximal DVT).
Regarding patients with bilateral DVT, rates of death and VTE recurrence were, respectively, for cancer-related iDDVT (n = 22) 86.4% (n = 19) and 18.2% (n = 4), for cancer-related isolated proximal DVT (n = 15) 80.0% (n = 12) and 6.7% (n = 1) and for iDDVT without cancer (n = 21) 23.8% (n = 5) and 23.8% (n = 5).
Sensitivity analysis
Sixty-five cancer-related iDDVT patients, 59 cancerrelated isolated proximal DVT patients and 120 iDDVT patients without cancer had no history of previous VTE and were thus considered for this analysis. As compared with patients with cancer-related isolated proximal DVT, patients with cancer-related iDDVT had a similar risk of death and major bleeding and a higher risk of VTE recurrence (Table 3) . As compared with iDDVT patients without cancer, patients with cancer-related iDDVT had a higher risk of death, major bleeding and VTE recurrence (Table 3 ).
Discussion
We found that the prognosis of patients with cancerrelated iDDVT was dramatically poorer than the prognosis of patients with iDDVT without cancer and appeared to be similar to the prognosis of patients with cancerrelated proximal DVT. Exclusion of patients with a previous history of VTE did not change the results.
Our study's primary objective was to describe the longterm prognosis in terms of death, VTE recurrence and bleeding among patients with cancer-related iDDVT and to compare it with patients with iDDVT and without cancer, and with patients with cancer-related isolated proximal DVT. It has been reported that cancer is a risk factor for proximal extension and VTE recurrence in patients with iDDVT [17] [18] [19] [20] [21] . We also previously showed that the risk of occult cancer and the prognosis of occult cancer were similar in patients with iDDVT and proximal DVT [22] . Here, we demonstrate that the clinical importance of iDDVT is dramatically different if it occurs in the context of cancer. Indeed, as compared with iDDVT patients without cancer matched for age and sex, the risk of death among patients with cancer-related iDDVT was almost 10 times significantly higher (38.3% per PY vs. Table 2 Comparison of incidences of adverse outcomes (death, VTE recurrence, VTE recurrence after stopping anticoagulants, major bleeding) during 3 years follow-up among patients with cancer-related iDDVT, cancer-related isolated proximal DVT and iDDVT without cancer. Values are percentages per patient-year [95% CI], (number of events) with calculation of the hazard ratio (HR) and 95% CI for the risk of death, the cause-specific hazard ratio (CHR) and 95% CI for the risk of VTE recurrence and major bleeding and the hazard ratio and cause-specific hazard ratio adjusted for age, sex, obesity and treatment, considered as a time-varying covariate (aHR and aCHR) However, given our observational design, our results must be interpreted cautiously: patients with isolated cancer-related proximal DVT were more frequently treated with anticoagulants (96.7% vs. 90.2%, P = 0.07) and for significantly longer duration (273 vs. 166 days, P = 0.02). Furthermore, in the absence of a high risk of bleeding, stopping anticoagulants in case of cancer-related DVT and persistence of an active malignancy is uncommon in the case of proximal DVT and certainly more frequent in the case of iDDVT. It is likely that those cancer-related proximal DVT patients who stopped anticoagulant treatment did it almost exclusively because their malignancy was considered to be cured; it has been demonstrated that, in this situation, the risk of VTE recurrence after stopping anticoagulants becomes similar to the risk of recurrence of VTE provoked by a transient risk factor [23] . Finally, it should also be emphasized that we did not note any major differences in cancer type and stage between patients with cancer-related iDDVT and patients with cancer-related isolated proximal DVT.
To our knowledge, no prospective study focusing on cancer-related iDDVT has been previously published. Recently, Dentali et al. presented an abstract describing the results of a retrospective muticenter study focusing on the prognosis of cancer-related iDDVT [24] . Similar to our study, they reported a very high risk of death (44.5%) and a similar risk of VTE recurrence (13.2% per PY). On the one hand, Dentali recruited three times more patients and therefore has a higher statistical power. On the other hand, our study was prospective, with a longer follow-up (up to 3 years vs. 12-24 months), and we were able to compare the prognosis of cancer-related iDDVT patients with that of iDDVT patients without cancer and cancer-related isolated proximal DVT patients, each matched on age and sex.
From a clinical practice point of view, our results demonstrate that the prognosis of cancer-related iDDVT is serious and must be considered differently to iDDVT without cancer, the prognosis of which is largely benign and for which the usefulness of a full dose of anticoagulants is still unclear [25] . Occurrence of an iDDVT in the course of a cancer has a similarly high risk of death to that in cancer-related proximal DVT. Such patients are also at very high risk of VTE recurrence, including proximal VTE events. The prognosis of bilateral cancer-related iDDVT was also particularly poor (86% case fatality rate at 3 years). Specific therapeutic studies are needed to determine the optimal duration of anticoagulant treatment in patients with cancer-related iDDVT.
A number of methodological aspects of our study deserve comment. Given our exclusion criteria, our results apply only to episodes of iDDVT with a clot diameter under compression of ≥ 5 mm. Telephone follow-up by a clinical research associate might have favored underreporting of VTE events. However, in OPTIMEV, our incidence at 3 years of VTE recurrence and recurrence as PE after a first isolated proximal DVT in patients without cancer was similar to that of Baglin's meta-analysis in which most studies, like ours, were observational (5.2% per patient-year vs. 6.1% per patient-year; 1.0% per patient-year vs. 0.9% per patient-year) [10] . From a statistical point of view, to be consistent with other methods used, (Kaplan-Meier and cause-specific hazard ratios), incidence rates of VTE recurrence and major bleeding were calculated with censoring patients at their death. Although this could have overestimated the incidence rates, it could not have modified the results of our comparisons between groups. Finally, we are aware that our results need to be confirmed by larger studies. Table 3 Comparison of incidences of adverse outcomes (death, VTE recurrence, major bleeding) during 3 years of follow-up among patients with a first cancer-related iDDVT (n = 65), a first cancer-related proximal DVT (n = 59) and a first iDDVT without cancer (n = 120). Values are percentages per patient-year [95% CI], (number of events) with calculation of the hazard ratio (HR) and 95% CI for the risk of death, the cause-specific hazard ratio (CHR) and 95% CI for the risk of VTE recurrence and major bleeding and the hazard ratio and cause-specific hazard ratio adjusted for age, sex, obesity and treatment, considered as a time-varying covariate (aHR and aCHR) The strengths of our study include its multicenter prospective design, a very low rate of losses to follow-up (0% of cancer-related iDDVT) and a systematic adjudication of all reported adverse outcomes by an expert committee after review of medical records. Its observational design provides data on long-term outcomes of patients with cancer-related iDDVT managed in routine clinical practice. All DVTs were diagnosed according to a standardized whole leg CUS exploration protocol performed by well-trained vascular medicine physicians and at baseline our proportion of distal and proximal DVTs was similar to that of a large meta-analysis [12] . In the absence of agreed diagnostic criteria, we considered as distal DVT only cases with a clot diameter under compression of ≥5 mm, in order to focus on high-risk DVT and limit the potential risk of false-positive CUS results. We were also able to match the populations of iDDVT and proximal DVT that we compared on age and sex and our results remained similar after excluding DVT patients with a history of previous VTE.
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